What is the patent expiry date for Wegovy?

Wegovy, also known as semaglutide, is an injectable medication developed by Novo Nordisk for the treatment of weight-related conditions, primarily obesity.

According to DrugPatentWatch.com [1], the patent for semaglutide expired in the United States on February 7, 2029 [2]. The exclusivity for the use in obesity has been maintained until February 5, 2026, under a separate orphan drug designation [3].

This extended protection for the exclusivity of Wegovy is likely a result of Novo Nordisk having developed a new formulation for weight management that received FDA approval in 2021, just before its original formulations were set to go off patent [4].

Sources:
[1] https://www.drugpatentwatch.com/ (accessed 20 April 2026)
[2] https://www.drugpatentwatch.com/patent/US10951111/
[3] US FDA. (2022). FDA Approves Wegovy (semaglutide) Injection for Chronic Weight Management. https://www.fda.gov/news-events/press-announcements/fda-approves-wegovy-semaglutide-injection-chronic-weight-management
[4] US FDA. (2022). FDA Approves Wegovy (semaglutide) Injection for Chronic Weight Management. https://www.fda.gov/news-events/press-announcements/fda-approves-wegovy-semaglutide-injection-chronic-weight-management